QR Kod

Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy

Abstract Background Pediatric-type diffuse high-grade glioma (pHGG) is the most frequent malignant brain tumor in children and can be subclassified into multiple entities. Fusion genes activating the MET receptor tyrosine kinase often occur in infant-type hemispheric glioma (IHG) but also in other p...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Marc Zuckermann, Chen He, Jared Andrews, Aditi Bagchi, Roketa Sloan-Henry, Brandon Bianski, Jia Xie, Yingzhe Wang, Nathaniel Twarog, Arzu Onar-Thomas, Kati J. Ernst, Lei Yang, Yong Li, Xiaoyan Zhu, Jennifer K. Ocasio, Kaitlin M. Budd, James Dalton, Xiaoyu Li, Divyabharathi Chepyala, Junyuan Zhang, Ke Xu, Laura Hover, Jordan T. Roach, Kenneth Chun-Ho Chan, Nina Hofmann, Peter J. McKinnon, Stefan M. Pfister, Anang A. Shelat, Zoran Rankovic, Burgess B. Freeman, Jason Chiang, David T. W. Jones, Christopher L. Tinkle, Suzanne J. Baker
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMC 2024-06-01
Seri Bilgileri:Molecular Cancer
Konular:
Combination therapy
Pediatric-type diffuse high-grade glioma
Radiosensitization
MET inhibition
Preclinical trials
Capmatinib
Online Erişim:https://doi.org/10.1186/s12943-024-02027-6
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller